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ABSTRACT 
Objectives: Capillary rarefaction is a hallmark of untreated 
hypertension. Recent data indicate that rarefaction may be 
reversed by antihypertensive treatment in nondiabetic hypertensive 
patients. Despite the frequent association of diabetes with 
hypertension, nothing is known on the capillaty density of treated 
diabetic patients with hypertension. 
Methods: We enrolled 21 normotensive healthy, 25 hypertensive 
only, and 21 diabetic (type 2) hypertensive subjects. All hypertensive 
patients were treated with a blocker of the renin-angiotensin system, 
and a majority had a home blood pressure :o;l35/85 mmHg. 
Capillary density was assessed with videomicroscopy on dorsal 
finger skin and with laser Doppler imaging on forearm skin 
(maximal vasodilation elicited by local heating). 
Results: There was no difference between any of the study 
groups in either dorsal finger skin capillary density (controls 
101 ± 11 capillaries/mm2, nondiabetic hypertensive 99 ± 16, 
diabetic hypertensive 96 ± 18, p > 0.5) or maximal blood flow in 
forearm skin (controls 666 ± 114 perfusion units, nondiabetic 
hypertensive 612 ± 126, diabetic hypertensive 620 ± 103, p > 0.5). 
Conclusions: Irrespective of the presence or not of type 2 
diabetes, capillary density is normal in hypertensive patients with 
reasonable control of blood pressure achieved with a blocker of 
the renin-angiotensin system. 
Key words: hypertension, capillaries, microcirculation, video-
microscopy, diabetes mellitus 
Abbreviation used: ACE, angiotensin-converting enzyme; ARB 
angiotensin receptor blocker; LDI, laser Doppler imaging; PU, 
perfusion units. 
Please cite this paper as: Aellen ), Dabiri A, Heim A, Liaudet L, Burnier M, Ruiz ), Feihl F, Waeber B. Preserved capillary density of dorsal finger skin in trea-
ted hypertensive patients with or without type 2 diabetes. Microcirculation 19: 554-562, 2012. 
INTRODUCTION 
The structural rarefaction of microvascular networks (capil-
lary rarefaction) in various organs and tissues is presently 
believed to be a hallmark of all forms of hypertension 
[17,37). Capillary rarefaction has been demonstrated in a 
variety of hypertensive experimental models, in tissues as 
diverse as skeletal muscle [8,10,21,35,44,48], myocardium 
[32,33,38,45-47,58], intestine [23], and skin [20). In 
humans, quantitative evaluation of capilla1y density is 
mainly possible in the superficial dermis, with videocapilla-
roscopy of nailfold or dorsal finger skin. To maximize the 
number of open and therefq,re visible vessels, counting is 
carried out with venous return occluded by inflation of a 
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finger or wrist cuff. With this method, skin capillary den-
sity has been consistently found to be 10-20% lower in 
patients with untreated hypertension, in comparison with 
normotensive controls [ 6, 13,43,49). This defect might be 
an early feature of hypertensive disease, as it was reported 
in borderline hypertensives [5], and even in normotensive 
offsprings of hypertensive parents [ 4). 
Uncertainty remains on whether capillary rarefaction is a 
secondary manifestation of hypertension (it certainly can 
be, as shown by its occurrence in experimental hyperten-
sion) or whether it also expresses a primary abnormality of 
the vascular system, which might be linked to the later 
development of hypertensive disease (as suggested by the 
aforementioned data in normotensive subjects). We are 
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also far from completely understanding the processes 
involved in the hypertensive reduction of capillary density. 
These are nevertheless increasingly thought of in terms of 
an imbalance between vessel destruction (e.g., endothelial 
cell apoptosis caused by oxidant stress [ 31], the latter pos-
sibly related to the abnormal, activation of membrane-
bound NADPH oxidase by angiotensin II) and regeneration 
through vasculogenesis and/ or angiogenesis [ 17]. Consis-
tent with this concept, cancer patients receiving antiangio-
genic therapy simultaneously develop hypertension and 
capillary rarefaction [41,55]. 
Whether a primary or secondary phenomenon, capillary 
rarefaction is increasingly believed to play a role in the patho-
genesis of hypertensive end-organ damage, notably by promot-
ing tissue ischemia [17,24]. It is thus important to know if it 
can be reversed by antihypertensive treatment. Many, although 
not all, experimental studies suggest a positive answer to this 
important question [17,24]. On the clinical side, two cross-sec-
tional surveys have reported that treated hypertensive patients 
in whom control of blood pressure was satisfactory had a high-
er-indeed normal, or even supranormal-capillary density in 
dorsal finger skin, in comparison with untreated [13] or unsat-
isfactorily treated patients [12]. In addition, a low-salt diet was 
associated with an increased skin capillary density when com-
pared with a high-salt diet in a cross-over trial carried out in 
mildly hypertensive subjects [22]. 
Of note, the aforementioned experimental and clinical 
studies have all been carried out in nondiabetic animals 
and patients. Diabetes and hypertension are frequently 
associated, aggressive lowering of blood pressure is particu-
larly important in this condition [2], and diabetes has a 
specific impact on the microcirculation. One might there-
fore wonder whether diabetes can also induce rarefaction, 
and how it could possibly interact with hypertensive disease 
in that respect. There is almost no information relevant to 
this question in the literature. 
In the present study, we have for the first time compared 
the skin capillary densities of hypertensive patients· with or 
without type 2 diabetes. In both groups, a similar level of 
blood pressure control was achieved by a drug regimen that 
included at least one blocker of the renin-angiotensin system. 
Capillary density, measured by two different methods, was 
found identical in both groups of subjects, and did not differ 
from values obtained in healthy normotensive volunteers. 
MATERIAL AND METHODS 
Subjects 
The study comprised three groups of subjects: hypertensive 
only, hypertensive and diabetic, and healthy normotensive 
volunteers (control). Enrolled subjects were caucasian, of 
either gender, aged 40-;;;70 years, and could be smokers or 
nonsmokers. 
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The patients, with or without diabetes, had been diag-
nosed and hypertensive according to current criteria by the 
European Society of Hypertension [16]. Hypertension 
could have been of any duration greater than two months, 
and must have been treated with a regimen including at 
least one blocker of the renin-angiotensin system for the 
last two months preceding enrollment into the study. This 
latter requirement was to improve the matching of the two 
hypertensive groups regarding drug treatment, as blockers 
of the renin-angiotensin system have become a compelling 
indication in hypertensive patients with diabetes. Hyperten-
sive patients were classified as nondiabetic in the absence 
of any corresponding medical history, and provided that 
fasting blood glucose was <5.6 mM at inclusion time [1]. 
Hypertensive diabetic patients had type 2 diabetes of any 
duration, attested by medical history and ongoing treat-
ment with either oral antidiabetic agents and/or insulin. 
At enrollment time, normotensive healthy volunteers had 
unremarkable medical history and standard clinical exami-
nation, a blood pressure <140/90 mmHg, a fasting blood 
glucose <5.6 mM [1], and a plasma creatinine <110 J.lM. 
For the subjects to be retained in the final analysis, all these 
criteria had to be fulfilled a second time, on the second visit 
taking place approximately three months later (see below). 
Pregnancy and active skin disease of any kind were 
exclusion criteria for all three groups. Hypertensive patients 
with or without diabetes were not included if on renal 
replacement therapy or with a plasma creatinine >250 J.lM. 
The enrollment of patients was through the relevant spe-
cialized outpatient clinics at our hospital. The recruitment 
of normotensive subjects was from hospital staff or through 
paper advertisement. The study was carried out in accor-
dance with the principles outlined in the Declaration of 
Helsinki and was approved by the Ethical Committee com-
petent for our institution. All participants gave written 
informed consent. 
Investigation of Capillary Density 
Capillaroscopy in dorsal finger skin. Skin capillaries were 
visualized with videomicroscopy in accordance with a 
methodology described by others [ 13]. The forearm was 
placed horizontally on an examination table, at heart level, 
with the subject in the sitting position. To maximize the 
number of visible capillary loops, venous congestion was 
created by inflating at 60 mmHg a miniature pressure cuff 
placed around the base of the middle finger. The dorsal 
skin of its second phalanx was imaged, using an epi-illumi-
nated fiber-optic microscope containing a 100 W halogen 
light source with a contact objective for a final magnifica-
tion of 200 (PV100, Fort Imaging Systems, Dourdan, 
France). The epidermis was made translucent with immer-
sion oil. The middle finger on the left and on the right side 
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were both examined in this fashion. Microscopic video 
sequences were transferred for storage and further analysis 
to a PC via a video image converter. Static images were 
later extracted for the counting of capillary loops in 10 
fields, 5 per side, each with an area of 1 mm2, using the 
Histolab software (Microvision, Paris, France). The final 
reported count was the mean of these 10 fields. This mean 
was used to calculate the descriptive statistics of the study, 
while statistical analysis was carried out on single counts 
(10 per subject) as explained below. 
The counting of capillaries on the static images of the whole 
study was carried out by the same observer, who was blinded 
to their origin. Preliminary work established a between-obser-
ver coefficient of variation of approximately 5o/o. 
Maximal vasodilation in forearm skin. Local heating to a 
temperature of 42-44°C elicits maximal vasodilation in the 
dermis of forearm skin, as can be assessed from the mea-
surement of dermal blood flow with laser Doppler flowme-
try [28,40]. In healthy subjects, the maximal dermal blood 
flow recorded in these conditions has been positively corre-
lated with capillary density measured as above [26,42]. In 
the present study, the maximal vasodilation induced by 
local heating in forearm skin was used as an additional 
index of capillary density. 
Dermal blood flow was assessed using a laser Doppler 
imager (LDI, Moor Instruments, Axminster, UK). With this 
device, a laser beam (633 nm) scans the skin from a distance, 
allowing the mapping of blood flow over an area, which may 
range from a few mm2 to 10 cm2 or more, depending on 
instrument settings. The raw data may be postprocessed to 
obtain spatial averages on user-chosen subareas of interest. 
Local heating was effected by means of custom made, 
annular, water-filled thermocontrolled chambers affixed to 
forearm skin with double-sided tape. An area of 0.8 cm2 of 
skin at the bottom of the chamber was accessible to the 
laser beam. The complete setup has been previously 
described by us in detail [11]. Two chambers were plated 
side-by-side, their temperature simultaneously raised from 
34 to 43°C and kept at that value for 15 minutes, a time 
sufficient for the stabilization of dermal blood flow, which 
was recorded in parallel on both spots by scanning with 
the LDI device. The maneuver was then repeated on the 
contralateral arm. The final value for maximal dermal blood 
flow was the average of data recorded on the four spots 
and was retained as an index of capillary density. This index 
was used to calculate the descriptive statistics of the study, 
while statistical analysis was carried out on single vasodila-
tory responses (four per subject), as explained below. 
Protocol 
The study comprised two vi~~s separated by approximately 
three months. Both visits took place in the same quieti\, 
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temperature-controlled room, between 8 and 11 a.m. on 
working days, with the subjects reporting in the fasting 
state. 
On Visit 1, criteria for eligibility and group allocation 
were checked. In all subjects, brachial blood pressure was 
measured (office BP) and peripheral venous blood was 
drawn for routine laboratory assessment, including blood 
glucose and plasma creatinine. Nothing more was done 
with normotensive volunteers, except scheduling the 
appointment for Visit 2. Hypertensive patients with or 
without diabetes were in addition given a validated oscillo-
metric device (Omron) for the self-measurement of bra-
chial blood pressure at home (home BP). They were 
instructed on its mode of operation and asked to carry out 
with it, in duplicate or preferably triplicate, two evalua-
tions per day (morning and evening) of their blood pres-
sure for the next three weeks. The appointment for Visit 2 
was set up, and the patients were asked to also record their 
blood pressure twice a day during the three preceding 
weeks. 
On Visit 2, home BP was retrieved from the oscillomet-
ric devices and stored on a computer. All measurements 
made on Visit 1 were repeated. Any healthy volunteer with 
an office BP ;:::140/90 mmHg was excluded from further 
examination. All other subjects were invited to recline on a 
hospital bed. After 20 minutes of rest, maximal skin vaso-
dilation was evaluated as described above. The subjects 
then were asked to sit at an examination table for the 
videomicroscopic determination of capillary density. 
Data Analysis 
For continuous variables, comparisons among the three 
groups were done with simple analysis of variance. For data 
regarding capillary density, four (thermal-induced vasodila-
tion) or 10 values (capillaroscopy) were available for each 
subject. In these cases, we used a mixed-model ANOVA, 
including a single fixed factor with three levels (group), 
and patients as a random factor nested under group. When 
the F value for the group effect was significant, pairwise 
comparisons were carried out with modified t-tests (Fish-
er's least significant differences). Chi-square tests were used 
for comparisons of categorical variables between groups. 
The alpha level of all tests was 0.05. Data are summarized 
as means± SD. 
RESULTS 
The study was completed by 67 subjects, 21 in the control 
group, 25 in the hypertensive only group, and 21 in the 
hypertensive + diabetic group. Their demographic and lab-
oratory data, as recorded at the time of capillary density 
investigation (i.e., Visit 2), are shown in Table 1. The 
healthy, normotensive volunteers were on the average 
© 2012 John Wiley & Sons Ltd 
Table 1. Demographic and laboratory data 
Control 
Number of subjects 21 
Demographic 
Gender (M/F) 10/11 
Age (years) 53± 8 
Height (em) 168 ± 9 
Weight (kg) 66.0 ± 11.8 
BMI (kg/m2) 23.3 ± 3.1 
Abdominal 86 ± 11 
circumference 
(em) 
Nonsmoker 18 
Laboratory 
Glucose (mM) 4.5 ± 0.5 
Creatinine (11M) 70 ± 18 
Total cholesterol 5.3 ± 0.8 
(mM) 
HDL(mM) 1.7 ± 0.6 
Total 3.4 ± 1.1 
cholesteroi/HDL 
Triglycerides 1.0 ± 0.5 
LDL (mM) 3.1 ± 0.9 
Hb 1Ac (%) 
Hypertensive Hypertensive 
only and diabetic 
25 21 
17/8 13/8 
61 ± 8** 61 ± 7** 
172 ± 10 171 ± 9 
80.4 ± 13.5** 92.1 ± 15.4**H 
27.0 ± 3.3** 31.5 ± 4.4**tt 
101 ± 9** 110 ± 13**H 
7** 5*"" 
5.5 ± 0.9** 6.7 ± 1.5**H 
84± 13** 78 ± 20 
5.9 ± 1.1 4.8 ± 1.2tt 
1.4 ± 0.4* 1.2 ± 0.4** 
4.6 ± 1.5** 4.4 ± 1.8* 
1.9 ± 1.1** 2.1 ± 1.1** 
3.7±1.0* 2.9±1.1j't 
6.7 ± 0.8 
Data recorded at the time of capillaroscopic examination (Visit 2), 
and presented as means ± SD. Control subjects were nonhyperten-
slve volunteers. *p < 0.05, **p < 0.01 vs Control tp < 0.05, H 
p < 0.01 hypertensive and diabetic vs hypertensive. 
somewhat younger (by seven years), markedly leaner, and 
more frequent smokers than their hypertensive counter-
parts. The two hypertensive groups were well matched for 
age, sex ratio, and smoking habits, while obesity was more 
prevalent in the diabetics (BMI 230 kglm2 in 5/25 hyper-
tensive patients without and 15/21 hypertensive patients 
with diabetes, p < 0.01). Blood glucose was somewhat 
higher in the hypertensive only and markedly higher in the 
hypertensive and diabetic patients, in comparison with the 
healthy normotensive subjects. Concerning the lipid profile, 
the expected generalized trend toward abnormality sepa-
rated the hypertensive only from the control group. Lipid 
abnormalities were less marked in hypertensive diabetics, 
who even had lower total cholesterol and identical LDL lev-
els when compared with healthy normotensive subjects. 
Concomitantly, respectively 8 and 15 of these 21 patients 
had an Hb1Ac level <6.5% and 7%, attesting to generally 
excellent control of diabetes in this group, a quality, which 
according to a recent survey, seems usual in Switzerland 
and other western european countries [ 7]. Table 2 presents 
data related to the control of blood pressure. Not unex-
pectedly, office BP W<lli higher in the two hypertensive 
group than in the control group, on both visits. In the 
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Table 2. Blood pressure at inclusion (Visit 1) and at the time of 
capillaroscoplc examination (Visit 2) 
Control 
Number of subjects 21 
Visit 1 
Office BP (mmHg) 
Systolic 121 ± 9 
Diastolic 78 ± 7 
Home BP (mmHg) 
Systolic 
Diastolic 
Visit 2 
Office BP (mmHg) 
Systolic 119 ± 10 
Diastolic 78 ± 7 
Home BP (mmHg) 
Systolic 
Diastolic 
Hypertensive 
only 
25 
139 ± 16** 
86 ± 8** 
133 ± 9 
82 ± 7 
136±15** 
85 ± 8** 
136 ± 3 
83 ± 7 
Hypertensive 
and diabetic 
21 
133 ± 19** 
81 ± 12 
128 ± 14 
77 ± 8t 
131 ± 13** 
81 ± 8 
130 ± 12 
78 ± 7t 
Visit 2 took place approximately three months after Visit 1. Control 
subjects were nonhypertensive volunteers. Home BP was recorded 
by hypertensive subjects, In the three weeks that followed Visit 1 
and the three weeks the preceded Visit 2. Data are means ± SD. 
*p < 0.05, **p < O.D1 vs Control. tp < 0.05 hypertensive and dia-
betic vs hypertensive. 
hypertensive only group, home BP was :::;135/85 mmHg 
during the three weeks following Visit 1 and the three 
weeks preceding Visit 2 in respectively 13 and 11 of 25 
patients. The corresponding numbers for the hypertensive 
and diabetic group were 15 and 14 of 21 patients. Thus, 
the overall quality of blood pressure control was somewhat 
better in the diabetics, but reasonable and relatively stable 
from Visit 1 to Visit 2 in both hypertensive groups. 
The antihypertensive medications currently received on 
both visits are listed in the upper part of Table 3. Per 
design, all patients were on at least an inhibitor of the 
angiotensin-converting enzyme or an angiotensin II recep-
tor antagonist on Visit 1, and remained so on Visit 2, with 
the rest of the medication changing very little between both 
visits. Antidiabetic medication was also quite stable from 
Visit 1 to Visit 2, with one-third of patients receiving insu-
lin on both occasions (lower part of Table 3). Finally, one 
half of hypertensive subjects were on lipid lowering ther-
apy, essentially with statins. 
Whether directly measured with capillaroscopy on dorsal 
finger skin or indirectly evaluated from maximal dermal 
blood flow on the forearm, capillary density did not differ 
between the three study groups (Table 4). In post-hoc anal-
ysis, none of these measurements of capillary density was 
correlated with either office BP, home BP, or HbA1c as 
recorded on Visit 2 (not shown). When using a threshold 
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Table 3. Medications taken by hypertensive patients 
Hypertensive 
only 
Hypertensive 
and diabetic 
Visit 1 Visit 2 Visit 1 Visit 2 
Renin-angiotensin system inhibitors 
ACE inhibitors only 8 7 10 10 
ARB only 17 18 10 10 
Both 0 0 1 1 
Other antihypertensive agents 
Diuretics 19 19 17 16 
{J-Biockers 7 7 6 5 
Calcium channels 10 11 2 2 
blockers 
Antidiabetic agents 
Oral only 13 13 
Insulin only 5 5 
Both 3 3 
Hypolipemlc agents 
Statins 13 11 10 14 
Fib rates 0 0 1 1 
ACE, angiotensin-converting enzyme; ARB angiotensin receptor 
blocker. 
Table 4. Microvascular density data 
Control 
Number of subjects 21 
Capillary density (dorsal finger skin) 
capillary loops/mm2 101 ± 11 
Skin blood flow (forearm skin) 
Baseline (PU) 78 ± 35 
Maximal (PU) 666 ± 114 
Increase from 588 ± 119 
baseline to 
max (PU) 
Hypertensive Hypertensive 
only and diabetic 
25 
99 ± 16 
84 ± 47 
512 ± 126 
528 ± 127 
21 
95 ± 18 
73 ± 22 
520 ± 103 
546 ± 101 
Capillary density was directly measured with vldeomicroscopy on 
dorsal finger skin. On forearm skin, microvascular density was Indi-
rectly estimated from the maximal response of dermal blood flow to 
15 minutes of local heating, from 34 (baseline) to 43°C (maximal). 
Skin blood flow, here expressed in perfusion units (PU), was 
recorded with laser Doppler imaging, on the volar face of forearms, 
in baseline conditions, and then after 15 minutes of local heating to 
a temperature of 43°C. Control subjects were nonhypertensive vol-
unteers. Data were obtained on Visit 2, and are presented as 
means± SD. There were not statistically significant between group 
differences. 
HbA1c of 6.5o/o to divide the diabetic patients into two 
subgroups, the mean and . .SD of capillary density were 
respectively 102 ± 19 cap/mm2 (HbA1c :>;6.5%, 11 == 12) 
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and 89 ± 15 cap/mm2 (HbA1c >6.5o/o, 11 == 9), a difference 
that was not statistically significant (p == 0.09). 
DISCUSSION 
In hypertensive patients who received a blocker of the 
renin-angiotensin system, we observed that capillary density 
was not reduced in comparison with a control group of 
healthy normotensive subjects, at least in dorsal finger and 
forearm skin. Our main new finding is that this statement 
holds independently of concomitant association of hyper-
tension with type 2 diabetes. 
As reviewed in the introduction, capillary rarefaction, 
whether assessed directly in dorsal finger skin [4,6,13,49,50], 
or indirectly in forearm skin [42], has essentially been docu-
mented in untreated nondiabetic hypertensives [6,13,49,50], 
or in normotensive nondiabetic subjects with risk factors for 
hypertension [4,42]. On the other hand, recent clinical stud-
ies have indicated that, at least in absence of diabetes, antihy-
pertensive treatment can positively impact capillaty 
rarefaction, or even completely normalize it, especially if the 
regimen includes an inhibitor of the renin-angiotensin sys-
tem [12,13,22]. The lack of capillary rarefaction noted in the 
present study in the nondiabetic hypertensive patients is in 
accord with this recent literature. In particular, the degree of 
blood pressure control achieved in this group was, at least 
on average (Table 1), the same as that reported in the patient 
groups with normal or supranormal capillary density in the 
two aforementioned studies by Debabbi et al. [12,13]. Col-
lectively, thesis studies, including the present one, support 
that capillary rarefaction, at least in the skin, is a hallmark of 
untreated hypertension, which may be reversed upon proper 
control of blood pressure, especially if carried out with 
blockers of the renin-angiotensin system. 
Our study is the first one to specifically address the poten-
tial interaction of diabetes and hypertension in the modula-
tion of capillary density. The information relevant to this 
question is surprisingly scarce in the literature, despite the 
frequent association of both diseases, and despite the major 
impact of diabetes on the microcirculation. Rarefaction was 
observed in skeletal muscle of obese Zucker rats [19,34], a 
model of type 2 diabetes, but these animals are also hyper-
tensive [57], and nondiabetic controls of similar blood pres-
sure were not available to these studies. In a murine 
normotensive model of type· 1 diabetes induced by stretozot-
ocin, several proangiogenic factors were downregulated and 
several antiangiogenic factors upregulated in skeletal muscle. 
These changes were associated with a reduced number of 
capillaries per muscle fiber, although the number of vessels 
per unit tissue cross-sectional area was not affected [30]. An 
abnormally low density of microvessels, selectively concern-
ing those with a diameter <30 ~tm, has been described in the 
conjunctiva of patients with type 2 diabetes [18]. The status 
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of blood pressure was not documented in that study. In 
another clinical study [27], capillary density was measured 
with videomicroscopy in dorsal finger skin of 15 type 2 
diabetics, 15 nondiabetic but glucose-intolerant subjects, and 
15 controls with normal glucose tolerance. These three 
groups were well matched for age, gender, body mass index 
and blood pressure level (diastolic <90 mmHg, systolic 
<160 mmHg), and no difference in capillary density was 
found between either [27]. Finally, skin capillary density, 
assessed from maximal thermally induced vasodilation, did 
not differ between normoglycemic, normotensive human 
adults with and without genetic predisposition to type 2 dia-
betes [36]. 
In the present study, the diabetic and nondiabetic hyper-
tensive patients were well matched for age (Table 1) and 
type of antihypertensive medication (Table 3). In addition, 
the quality of blood pressure control, assessed from 2 three-
week periods of home BP monitoring, was good in both 
groups (Table 2). Furthermore, management of diabetes 
was next to optimal, as attested by the high proportion of 
patients with satisfactory control of HbA1c, and the rela-
tively mild alterations noted in the lipid profile of this 
group (Table 1). Our results (Table 4) indicate that, in such 
conditions, irrespective of the presence or absence of type 2 
diabetes, well-controlled hypertension is not associated with 
capillary rarefaction, at least in the skin microcirculation. If, 
as seems likely from the information reviewed above, hyper-
tension-associated capillary rarefaction is reversible upon 
proper control of blood pressure, then our results mean that 
concomitant diabetes has no bearing on such reversibility. 
The reasons for this state of affairs cannot be inferred 
from our data, and can only be speculated upon. We may 
note, for example, that the diabetic state has profound, and 
at times contradictory, influences on postnatal angiogene-
sis, which it may stimulate, due to local ischemia related to 
microvascular obstruction, as in the case of proliferative 
retinopathy [56], or hampered, among others by inducing 
dysfunction of crucial players such as endothelial progeni-
tor cells [15,54,56]. Our data convey some suggestion that 
the quality of glucose control has an impact, as capillary 
density tended to be lowest in those diabetics with HbA1c 
above 6.5%. This possibility would be consistent with the 
negative impact of hyperglycemia on the number and func-
tion of endothelial progenitor cells noted in several studies 
[ 25,39]. For its evaluation, a larger number of patients with 
more heterogenous metabolic control than in the present 
study would obviously be needed. 
Limitations 
The present study did not include groups of untreated 
hypertensive patients. With hypertensive diabetics, this 
would not have been ethically feasible, considering the par-
amount importance of blood pressure lowering in this con-
© 2012 John Wiley & Sons Ltd 
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clition [2]. Thus, the possibility remains that, regarding 
impact on capillary density, the natural history of com-
bined diabetes and hypertension might differ from that of 
hypertension alone. In addition, conclusions might only be 
valid for patients with fairly well-controlled hypertension 
and diabetes, as was the case in the present study. 
Capillary density in the skin tends to decrease with age 
[29], and the normotensive subjects were of younger age 
than the hypertensive patients (Table 1). This factor might 
have confounded comparisons between patients and con-
trols, making it more difficult to detect the supranormal 
capillary density associated with good control of blood 
pressure, as observed in one of the studies cited above 
[12]. On the other hand, age was identical in diabetic and 
nondiabetic hypertensives, and therefore could nor influ-
ence comparisons made between these two groups. 
In comparison with some of the previously mentioned 
reports, we have included a smaller number of subjects, which 
might leave our results open to the possibility of type II error. 
Calculations assuming 20 subjects per group (i.e., slightly less 
than the actual figures) and based on the within-subject vari-
ability of our capillaroscopic data indicate that the power to 
detect a 13% difference in the mean capillary density of any 
two groups was 0.8 at an alpha level of 0.05. The differences 
reported by Debabbi et al. between the mean number of capil-
laries/mm2 of age-matched normotensive subjects and 
hypertensive patients who were either untreated [ 13] or 
poorly controlled [12] were respectively 15% and 14%. We 
would have been unlikely to miss effects of that size. 
The respective contributions to our results of blood pres-
sure lowering vs other, pressure-independent effects of the 
various drugs administered to the patients remain a matter 
of conjecture. Roughly half of the hypertensive subjects were 
on lipid-lowering therapy with statins (Table 3), compounds 
with known proangiogenic properties [ 14,51]. In an effort to 
reduce heterogeneity, the enrollment of patients was 
restricted to those receiving a blocker of the renin-angioten-
sin system, and there is strong experimental evidence for a 
pro angiogenic effect of this drug class too [ 52,53,59]. 
Finally, while in man the skin is the main available win-
dow into microcirculation, one may question whether it is 
representative of other vascular beds. This issue is not likely 
to be resolved in the near future. There is, however, some 
evidence for a correlation between abnormalities in the skin 
microcirculation and in other parts of the cardiovascular 
system. In patients with essential hypertension, a parallelism 
was described between the respective time courses of coro-
nary flow reserve on one hand, and structural remodeling of 
small subcutaneous arteries on the other [9]. As another 
example, in a group of heart transplant recipients with 
greatly reduced exercise capacity, vasodilation induced by 
iontophoresis of acetylcholine in forerarm skin correlated 
with maximal 0 2 uptake as measured in a treadmill test [3]. 
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In summary, the present study confirms the absence of 
capillary rarefaction in nondiabetic hypertensive patients in 
whom blood pressure is reasonably well controlled by drug 
treatment. It further indicates, for the first time, that this 
statement extends to hypertension combined with type 2 
diabetes. This conclusion is at least valid if the drug regi-
men includes a blocker of the renin-angiotensin system, as 
was systematically the case here. 
ACKNOWLEDGMENTS 
PERSPECTIVE 
The authors thank Guy Berset for excellent technical assis-
tance, Pedro Marques-Vidal for statistical advice, and Steve 
Ayrton for English language editing. 
SOURCE OF FUNDING 
The study was funded by grant 32003B-116511 from the 
Swiss National Science Foundation. 
The present results add to the growing body of literature, 
indicating that hypertension-related capillary rarefaction 
may be reversible with proper treatment [12,13,22]. Future 
longitudinal studies should address the relationship of cap-
illary density to ultimate cardiovascular outcome in both 
diabetic and nondiabetic hypertensive populations. 
CONFLICT OF INTEREST 
None for any of the authors. 
REFERENCES 
1. American Diabetes Association. Diagnosis 
and classification of diabetes mellitus. Dia-
betes Care 28(Suppl 1 ): S37-S42, 2005. 
2. American Diabetes Association. Treatment 
of hypertension in adults with diabetes. 
Diabetes Care 26(Suppl1): S80-S82, 2003. 
3. Andreassen AK, Kvernebo K, Jorgensen B, 
Simonsen S, Kjekshus J, Gullestad L. Exer-
cise capacity in heart transplant recipients: 
relation to impaired endothelium-depen-
dent vasodilation of the peripheral micro-
circulation. Am Heart J 136: 320-328, 
1998. 
4. Antonios TFT, Rattray FM, Singer DRJ, 
Markandu ND, Mortimer PS, MacGregor 
GA. Rarefaction of skin capillaries in nor-
motensive offspring of individuals with 
essential hypertension. Heart 89: 175-
178, 2003. 
5. Antonios TFT, Singer DRJ, Markandu ND, 
Mortimer PS, MacGregor GA. Rarefaction 
of skin capillaries in borderline essential 
hypertension suggests an early structural 
abnormality. Hypertension 34: 655-658, 
1999. 
6. Antonios TFT, Singer DRJ, Markandu ND, 
Mortimer PS, MacGregor GA. Structural 
skin capillary rarefaction in essential 
hypertension. Hypertension 33: 998-
1001, 1999. 
7. Banegas JR, Lopez-Garcia E, Dallongeville 
J, Guallar E, Halcox JP, Borghi C, Masse-
Gonzalez EL, Jimenez FJ, Perk J, Steg PG, 
De Backer G, Rodriguez-Artalejo F. 
Achievement of treatment goals for pri-
mary prevention of cardiovascular disease 
in clinical practice across Europe: the 
EURIKA study. Eur Heart J ':32: 2143-
2152,2011. 
560 
8. Boegehold MA, Johnson MD, Overbeck 
HW. Pressure-independent arteriolar rare-
faction in hypertension. Am J Physiol 261: 
H83-H87, 1991. 
9. Buus NH, Bottcher M, Jorgensen CG, 
Christensen KL, Thygesen K, Nielsen TI, 
Mulvany MJ. Myocardial perfusion during 
long-term angiotensin-converting enzyme 
inhibition or beta-blockade in patients 
with essential hypertension. Hypertension 
44:465-470,2004. 
10. Chen II, Prewitt RL, Dowell RF. Microvas-
cular rarefaction in spontaneously hyper-
tensive rat cremaster muscle. Am J Physiol 
241: H306-H310, 1981. 
11. Ciplak M, Pasche A, Heim A, Haeberli C, 
Waeber B, Liaudet L, Feihl F, Engelberger 
R. The vasodilatory response of skin 
microcirculation to local heating is subject 
to desensitization. Microcirculation 16: 
265-275, 2009. 
12. Debbabi H, Bonnin P, Levy Bl. Effects of 
blood pressure control with perindop-
rillindapamide on the microcirculation in 
hypertensive patients. Am J Hypertension 
23:1136-1143,2010. 
13. Debbabi H, Uzan L, Mourad JJ, Safar M, 
Levy Bl, Tibirica E. Increased skin capillary 
density in treated essential hypertensive 
patients. Am J Hypertension 19: 477-483, 
2006. 
14. Dimmeler S, Aicher A, Vasa M, Mildner-
Rihm C, Adler K, Tiemann M, Rutten H, 
Fichtlscherer S, Martin H, Zeiher AM. 
HMG-CoA reductase inhibitors (statins) 
increase endothelial progenitor cells via 
the PI 3-kinase/ Akt pathway. J Clin Invest 
108: 391-397, 2001. 
15. Dimmeler S, Leri A. Aging and disease as 
modifiers of efficacy of cell therapy. Circ 
Res 102: 1319-1330, 2008. 
16. European Society of Hypertension-Euro-
pean Society of Cardiology. 2003 Euro-
pean Society of Hypertension-European 
Society of Cardiology guidelines for the 
management of arterial hypertension. J 
Hypertens 21: 1011-1053,2003. 
17. Feihl F, Liaudet L, Waeber B, Levy Bl. 
Hypertension, a disease of the microcircu-
lation? Hypertension 48: 1012-1017, 
2006. 
18. Fenton BM, Zweifach BW, Worthen DM. 
Quantitative morphometry of conjunctival 
microcirculation in diabetes mellitus. 
Microvasc Res 18: 153-166, 1979. 
19. Frisbee JC. Remodeling of the skeletal 
muscle microcirculation increases resis-
tance to perfusion in obese Zucker rats. 
Aml Physiol 285: H104-H111, 2003. 
20. Haack DW, Schaffer JJ, Simpson JG. Com-
parisons of cutaneous microvessels from 
spontaneously hypertensive, normotensive 
Wistar-Kyoto, and normal Wistar rats. Proc 
Soc Exp Bioi Med 164: 453-458, 1980. 
21. Hansen-Smith F, Greene AS, Cowley AW 
Jr, Lombard JH. Structural changes during 
microvascular rarefaction in chronic hyper-
tension. Hypertension 15: 922-928, 1990. 
22. He FJ, Marciniak M, Markandu ND, An-
tonics TF, MacGregor GA. Effect of mod-
est salt reduction on skin capillary 
rarefaction in white, black, and Asian indi-
viduals with mild hypertension. Hyperten-
sion 56: 253-259, 2010. 
23. Henrich H, Hertel R, Assmann R. Struc-
tural differences in the mesentery micro-
circulation between normotensive and 
spontaneously hypertensive rats. Pflugers 
Archiv 375: 153-159, 1978. 
24. Humar R, Zimmerli L, Battegay E. Angio-
genesis and hypertension: an update. J 
Human Hypertens 23: 773-782, 2009. 
© 2012 John Wiley & Sons Ltd 
25. Ingram DA, Lien IZ, Mead LE, Estes M, 
Prater DN, Derr-Yellin E, DiMeglio lA, 
Haneline LS. In vitro hyperglycemia or a 
diabetic intrauterine environment reduces 
neonatal endothelial colony-forming cell 
numbers and function. Diabetes 57: 724-
731, 2008. 
26. Irving RJ, Walker BR, Noon JP, Watt 
GCM, Webb DJ, Shore AC. Microvascular 
correlates of blood pressure, plasma glu-
cose, and insulin resistance in health. Car-
diovasc Res 53: 271-276, 2002. 
27. Jaap AJ, Shore AC, Stockman AJ, Tooke 
JE. Skin capillary density in subjects with 
impaired glucose tolerance and patients 
with type 2 diabetes. Diabetic Med 13: 
160-164, 1996. 
28. Kellogg DL Jr, Pergola PE, Piest KL, Kosiba 
WA, Crandall CG, Grossmann M, Johnson 
JM. Cutaneous active vasodilation in 
humans is mediated by cholinergic nerve 
cotransmission. Circ Res 77: 1222-1228, 
1995. 
29. Kelly Rl, Pearse R, Bull RH, Leveque JL, de 
Rigal J, Mortimer PS. The effects of aging 
on the cutaneous microvasculature. JAm 
Acad Dermato/33: 749-756, 1995. 
30. Kivela R, Silvennoinen M, Touvra AM, Le-
hti TM, Kainulainen H, Vihko V. Effects of 
experimental type 1 diabetes and exercise 
training on angiogenic gene expression 
and capillarization in skeletal muscle. 
FASEB J 20: 1570-1572, 2006. 
31. Kobayashi N, Delano FA, Schmid-
Schsnbein GW. Oxidative stress promotes 
endothelial cell apoptosis and loss of mi-
crovessels in the spontaneously hyperten-
sive rats. Arteriosc/er Thromb Vase Bioi 
25:2114-2121,2005. 
32. Kobayashi N, Kobayashi K, Hara K, Hig-
ashi T, Yanaka H, Yagi S, Matsuoka H. 
Benidipine stimulates nitric oxide synthase 
and improves coronary circulation in 
hypertensive rats. Am J Hypertension 12: 
483-491, 1999. 
33. Larouche I, Schiffrin EL. Cardiac microvas-
culature in DOCA-salt hypertensive rats: 
effect of endothelin ET(A) receptor antag-
onism. Hypertension 34: 795-801, 1999. 
34. Lash JM, Sherman WM, Hamlin RL. Capillary 
basement membrane thickness and capil-
lary density in sedentary and trained obese 
Zucker rats. Diabetes 38: 854-860, 1989. 
35. le Noble JL, Tangelder GJ, Slaaf DW, van 
Essen H, Reneman RS, Struyker-Boudier 
HA. A functional morphometric study of 
the cremaster muscle microcirculation in 
young spontaneously hypertensive rats. J 
Hypertens 8: 741-748, 1990. 
36. Lee BC, Shore AC, Humphreys JM, Lowe 
GD, Rumley A, Clark PM, Hattersley AT, 
Tooke JE. Skin microv~cular vasodilatory 
© 2012 John Wiley & Sons Ltd 
capacity in offspring of two parents with 
Type 2 diabetes. Diabetic Med 18: 541-
545, 2001. 
37. Levy Bl, Ambrosio G, Pries AR, Struijker-
Boudier HAJ. Microcirculation in hyperten-
sion - A new target for treatment? Circu-
lation 104: 735-740, 2001. 
38. Levy Bl, Duriez M, Samuel JL. Coronary 
microvasculature alteration in hypertensive 
rats. Effect of treatment with a diuretic 
and an ACE inhibitor. Am J Hypertension 
14: 7-13, 2001. 
39. Loomans CJ, van Haperen R, Duijs JM, 
Verseyden C, de Cram R, Leenen PJ, 
Drexhage HA, de Boer HC, de Koning EJ, 
Rabelink TJ, Staal FJ, van Zonneveld AJ. 
Differentiation of bone marrow-derived 
endothelial progenitor cells is shifted into 
a proinflammatory phenotype by hyper-
glycemia. Mol Med 15: 152-159, 2009. 
40. Minson CT, Berry LT, Joyner MJ. Nitric 
oxide and neurally mediated regulation of 
skin blood flow during local heating. J 
Appl Physio/91: 1619-1626, 2001. 
41. Mourad JJ, des Guetz G, Debbabi H, Levy 
Bl. Blood pressure rise following angio-
genesis inhibition by bevacizumab. A cru-
cial role for microcirculation. Ann Oneal 
19: 927-934, 2008. 
42. Noon JP, Walker BR, Webb DJ, Shore AC, 
Holton DW, Edwards HV, Watt GC. 
Impaired microvascular dilatation and cap-
illary rarefaction in young adults with a 
predisposition to high blood pressure. J 
Clin Invest 99: 1873-1879, 1997. 
43. Prasad A, Dunnill GS, Mortimer PS, Mac-
Gregor GA. Capillary rarefaction in the 
forearm skin in essential hypertension. J 
Hypertens 13: 265-268, 1995. 
44. Prewitt RL, Chen II, Dowell R. Develop-
ment of microvascular rarefaction in the 
spontaneously hypertensive rat. Am J 
Physio/243: H243-H251, 1982. 
45. Rakusan K, Cicutti N, Kazda S, Turek Z. 
Effect of nifedipine on coronary capillary 
geometry in normotensive and hyperten-
sive rats. Hypertension 24: 205-211, 
1994. 
46. Rakusan K, Cicutti N, Maurin A, Guez D, 
Schiavi P. The effect of treatment with 
low dose ACE inhibitor and/or diuretic on 
coronary microvasculature in stroke-prone 
spontaneously hypertensive rats. Micro-
vase Res 59: 243-254, 2000. 
47. Sabri A, Samuel JL, Marotte F, Poitevin P, 
Rappaport L, Levy 81. Microvasculature in 
angiotensin 11-dependent cardiac hypertro-
phy in the rat. Hypertension 32: 371-375, 
1998. 
48. Scheidegger KJ, Wood JM, van Essen H, 
Struijker-Boudier HA. Effects of prolonged 
blockade of the renin angiotensin system 
Capillary Density, Hypertension, Diabetes 
on striated muscle microcirculation of 
spontaneously hypertensive rats. J Phar-
macal Exp Ther 278: 1276-1281, 1996. 
49. Serne EH, Gans ROB, ter Maaten JC, Tang-
elder GJ, Danker AJM, Stehouwer CDA. 
Impaired skin capillary recruitment in 
essential hypertension is caused by both 
functional and structural capillary rarefac-
tion. Hypertension 38: 238-242, 2001. 
50. Serne EH, Gans ROB, ter Maaten JC, ter 
Wee PM, Danker AM, Stehouwer CDA. 
Capillary recruitment is impaired in essen-
tial hypertension and relates to insulin's 
metabolic and vascular actions. Cardiovasc 
Res49: 161-168,2001. 
51. Shao H, Tan Y, Eton D, Yang Z, Uberti 
MG, U S, Schulick A, Yu H. Statin and 
stromal cell-derived factor-1 additively 
promote angiogenesis by enhancement of 
progenitor cells incorporation into new 
vessels. Stem Cells 26: 1376-1384, 2008. 
52. Silvestre JS, Bergaya S, Tamarat R, Duriez 
M, Boulanger CM, Levy 81. Proangiogenic 
effect of angiotensin-converting enzyme 
inhibition is mediated by the bradykinin 
8(2) receptor pathway. Circ Res 89: 678-
683, 2001. 
53. Silvestre JS, Tamarat R, Senbonmatsu T, 
lcchiki T, Ebrahimian T, lglarz M, Besnard 
S, Duriez M, lnagami T, Levy Bl. Antiangi-
ogenic effect of angiotensin II type 2 
receptor in ischemia-induced angiogenesis 
in mice hindlimb. Circ Res 90: 1072-
1079, 2002. 
54. Sorrentino SA, Bahlmann FH, Besler C, 
Muller M, Schulz S, Kirchhoff N, Doerries 
C, Horvath T, Umbourg A, Umbourg F, 
Fliser D, Hailer H, Drexler H, Landmesser 
U. Oxidant stress impairs in vivo reend-
othelialization capacity of endothelial pro-
genitor cells from patients with type 2 
diabetes mellitus: restoration by the per-
oxisome proliferator-activated receptor-
gamma agonist rosiglitazone. Circulation 
116: 163-173,2007. 
55. Steeghs N, Gelderblom H, Roodt JO, 
Christensen 0, Rajagopalan P, Havens M, 
Putter H, Rabelink TJ, de Koning E. Hyper-
tension and rarefaction during treatment 
with telatinib, a small molecule angiogen-
esis inhibitor. Clin Cancer Res 14: 3470-
3476, 2008. 
56. Tan K, Lessieur E, Cutler A, Nerone P, 
Vasanji A, Asosingh K, Erzurum S, Anand-
Apte B. Impaired function of circulating 
CD34(+) CD45(-) cells in patients with 
proliferative diabetic retinopathy. Exp Eye 
Res 91: 229-237, 2010. 
57. van Zwieten PA. Diabetes and hyperten-
sion: experimental models for pharmaco-
logical studies. Clin Exp Hypertension 21: 
1-16, 1999. 
561 
J. Aellen et a/. 
58. Xie Z, Gao M, Togashi H, Saito H, Koy-
ama T. Improvement in the capillarity of 
the left ventricular wall of stroke-prone 
spontaneously hypertensive rats following 
angiotensin II receptor blockade. Clinical 
562 
& Experimental Hypertension 21: 441-
452, 1999. 
59. You D, Cochain C, Loinard C, Vilar J, 
Mees B, Duriez M, Levy 81, Silvestre JS. 
Hypertension impairs postnatal vasculo-
Bibliothequ8 Universitaire 
de Medecine 1 BiUM 
CHUV-BH08 - Bugnon 46 
CH -1011 Lausanne 
genesis: role of antihypertensive agents. 
Hypertension 51: 1537-1544, 2008. 
© 2012 John Wiley & Sons Ltd 
